In yet another instance of India Inc occupying a larger seat in the global league tables,three out of the top 10 fastest-growing generic companies globally are now from India. Besides being an indication of the acceptance of domestic pharmaceutical companies and their growing clout, this is also a stamp of their command on manufacturing processes, innovation and marketing muscle at a global scale.On the list is Glenmark Pharmaceuticals which, with a growth of 37%, is the fifth fastest growing generic company globally,followed by Dr Reddy’s which grew34% in FY 2011-12, according to global pharmaceutical research firm, Evaluate Pharma. The third domestic company on the list, Sun Pharma witnessed a growth of 29%, occupying the eighth rank, right below its subsidiary Taro which had a 33%growth (Taro reports its own numbers since it’s listed in the US, while the domestic company has started combining the Israel-based company’s financials since September 2010).The club of the fastest growing generic companies in the world is dominated by US companies, led by US-based Sagent Pharma, which witnessed a huge growth of 106%during the period, according to the research firm’s latest analysis.Perrigo, another US company, is the world’s second fastest-growing company with an 80% growth. Nichi-Iko Pharmaceutical of Japan is on thethird slot, posting a growth of 79%,while Watson Pharma of US grew 46%during the period.Pharma companies have taken advantage of the blockbuster drugswhich are losing patent protection,and have already raked in millions of dollars by introducing their copy-catversions. For instance, Dr Reddy’slaunched generic versions ofblock buster drugs Zyprexa and Plavix,while Ranbaxy mopped up hugerevenues from sales of generic Lipitor. Significant product launches, market exclusivity of drugs going offpatent,and growth in regulated markets have contributed to the development, industry experts say. According to Sujay Shetty, India leader for pharma and life sciences at PwC India, “This shows the growingsignificance of domestic companies interms of quality, portfolio strategy and certain significant first-to-file(FTF) products. Strong revenues fromregulated markets are another factor which contributed to the huge growth. Most of the companies have sales of around 50% coming from US, which isthe largest market for generics globally. Domestic companies like DrReddy’s capitalized on key FTF opportunities, while others including Sun Pharma posted gains on account of US sales.”The growth in domestic companieshas also been driven by their robusthome businesses. The Indian pharmamarket is clocking a growth of around15-20% year-on-year. Commenting on Glenmark’s strategy, CMD Glenn Saldanha says,”The high growth is due to our focusin building a strong emerging markets business in addition to having significant presence in India and US.The growth from markets, particularly Russia, Brazil and the US, has been exceptional. We have invested in these markets for the lastsix-seven years and we are just beginning to make huge inroads in these markets. Glenmark will continue to build its presence in markets like Russia, Brazil and Mexico where it has invested for the last five years and these markets willdrive strong growth.”